search
Back to results

Evaluation of the Safety and Immunogenicity of Hepatitis A Vaccine

Primary Purpose

Vaccination

Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun
Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang
Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS
Sponsored by
China National Biotec Group Company Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Vaccination

Eligibility Criteria

18 Months - 24 Months (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. subjects aged from 18 to 24 months old at the date of recruitment;
  2. with informed consent signed by parent(s) or guardians;
  3. parent(s) or guardians are able to attend all planned clinical appointments and obey and follow all study instructions;
  4. subjects have not been vaccinated with any type of Hepatitis A vaccines;
  5. subjects have no Hepatitis A disease and contraindication of vaccination;
  6. subjects did not receive any vaccines within 14 days;
  7. before joining this trial, subjects must be qualified and passed their medical history and clinical examinations, and axillary's temperature must be ≤37℃.

Exclusion Criteria:

  1. Subjects with history of allergy, convulsion, epilepsy, encephalopathy and psychosis or family history;
  2. Allergic to any ingredient of vaccine or with allergy history to any vaccine;
  3. Patients with immunodeficiency, in process of cancer treatment, immunosuppressive therapy (oral steroids) or HIV induced hypoimmunity, or in close contact with any family members who has congenital immune diseases;
  4. Receive non-specific immunoglobulin within 1 month before recruitment;
  5. Subjects with acute febrile diseases with body temperature > 37.0 ℃ or infectious diseases;
  6. Subjects with a history of thrombocytopenia or other coagulation disorders that may be contraindicated for hypodermic injection;
  7. With known or suspected concurrent diseases include respiratory disease, acute infection or active chronic disease;
  8. With severe cardiovascular diseases (Pulmonary heart disease, Pulmonary edema, hypertension cannot be controlled to normal range by drugs), liver and kidney diseases and diabetic complications;
  9. Various infectious, suppurative or allergic dermatitis;
  10. Other circumstances judged by investigators that are not suitable for this clinical trial.

Sites / Locations

  • Yangxian Center for Disease Control and Prevention
  • Mianxian Center for Disease Control and Prevention

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

Research Group 1

Research Group 2

Research Group 3

Arm Description

150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun Institute of Biological Products Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.

150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang Pukang Biotechnology Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.

150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. at the age of 18-24 months old, 1.0 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.

Outcomes

Primary Outcome Measures

Antibody Seroconversion rate
Blood samples were collected before and 30 (+ 10) days after immunization. Antibody level and antibody seroconversion rate of HAV-IgG will detect in laboratory. The antibody seroconversion rate of HAV-IgG must maintain the baseline as the other two comparators' products.

Secondary Outcome Measures

Antibody Geometric Mean Titer (GMT)
Antibody GMT will detect in laboratory. The antibody GMT must maintain the baseline as the other two comparators' products.
Adverse Events Incidence rate
Analyse the numbers and rates of participants who suffered from adverse events following immunization.

Full Information

First Posted
October 28, 2020
Last Updated
February 24, 2021
Sponsor
China National Biotec Group Company Limited
Collaborators
Changchun Institute of Biological Products Co., Ltd., Shaanxi Provincial Center for Disease Control and Prevention, Mianxian Center for Disease Control and Prevention, Yangxian Center for Disease Control and Prevention, Peking University
search

1. Study Identification

Unique Protocol Identification Number
NCT04612634
Brief Title
Evaluation of the Safety and Immunogenicity of Hepatitis A Vaccine
Official Title
A Randomized, Parallel Controlled Clinical Trial of the Safety and Immunogenicity of Hepatitis A (Live) Vaccine, Freeze-dried in Children Aged 18-24 Months Old
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Unknown status
Study Start Date
November 12, 2020 (Actual)
Primary Completion Date
January 13, 2021 (Actual)
Study Completion Date
July 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
China National Biotec Group Company Limited
Collaborators
Changchun Institute of Biological Products Co., Ltd., Shaanxi Provincial Center for Disease Control and Prevention, Mianxian Center for Disease Control and Prevention, Yangxian Center for Disease Control and Prevention, Peking University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Subjects will be recruited and divided into 3 groups: Hepatitis A(Live)Vaccine,Freeze-dried produced by Changchun Institute of Biological Products Co., Ltd Hepatitis A(Live)Vaccine,Freeze-dried produced by Zhejiang Pukang Biotechnology Co., Ltd., and Hepatitis A(Live)Vaccine,Freeze-dried produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. After immunization, the immunogenicity and safety of three different manufacturers will be compared and the data will be analyzed.
Detailed Description
To evaluate the safety and immunogenicity of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchhun Institute of Biological Products Co., Ltd, we design this randomized, parallel controlled study. 450 subjects are divided into 3 groups, including 1 experimental group and 2 control groups (Research Group 1, 2, and 3), each group assigned 150 subjects respectively. All subjects are aged 18-24 months old. 150 subjects from Research Group 1 will be administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchhun Institute of Biological Products Co., Ltd. Blood samples are collected before vaccination and one month (30 days) later. 150 subjects from Research Group 2 will be administrated with one dose of Hepatitis A(Live)Vaccine,Freeze-dried produced by Zhejiang Pukang Biotechnology Co., Ltd. Blood samples are collected before vaccination and one month (30 days) later. 150 subjects from Research Group 3 will be administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. Blood samples are collected before vaccination and one month (30 days) later. To evaluate the immunogenicity, we will detect and compare the seroconversion rates, and antibody geometric mean concentrations. The safety of all groups will be monitored as well.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vaccination

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
450 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Research Group 1
Arm Type
Experimental
Arm Description
150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun Institute of Biological Products Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
Arm Title
Research Group 2
Arm Type
Active Comparator
Arm Description
150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang Pukang Biotechnology Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
Arm Title
Research Group 3
Arm Type
Active Comparator
Arm Description
150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. at the age of 18-24 months old, 1.0 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
Intervention Type
Biological
Intervention Name(s)
Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun
Intervention Description
Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun. 0.5ml per dose
Intervention Type
Biological
Intervention Name(s)
Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang
Intervention Description
Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang. 0.5ml per dose.
Intervention Type
Biological
Intervention Name(s)
Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS
Intervention Description
Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml per dose.
Primary Outcome Measure Information:
Title
Antibody Seroconversion rate
Description
Blood samples were collected before and 30 (+ 10) days after immunization. Antibody level and antibody seroconversion rate of HAV-IgG will detect in laboratory. The antibody seroconversion rate of HAV-IgG must maintain the baseline as the other two comparators' products.
Time Frame
4 months
Secondary Outcome Measure Information:
Title
Antibody Geometric Mean Titer (GMT)
Description
Antibody GMT will detect in laboratory. The antibody GMT must maintain the baseline as the other two comparators' products.
Time Frame
4 months
Title
Adverse Events Incidence rate
Description
Analyse the numbers and rates of participants who suffered from adverse events following immunization.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Months
Maximum Age & Unit of Time
24 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: subjects aged from 18 to 24 months old at the date of recruitment; with informed consent signed by parent(s) or guardians; parent(s) or guardians are able to attend all planned clinical appointments and obey and follow all study instructions; subjects have not been vaccinated with any type of Hepatitis A vaccines; subjects have no Hepatitis A disease and contraindication of vaccination; subjects did not receive any vaccines within 14 days; before joining this trial, subjects must be qualified and passed their medical history and clinical examinations, and axillary's temperature must be ≤37℃. Exclusion Criteria: Subjects with history of allergy, convulsion, epilepsy, encephalopathy and psychosis or family history; Allergic to any ingredient of vaccine or with allergy history to any vaccine; Patients with immunodeficiency, in process of cancer treatment, immunosuppressive therapy (oral steroids) or HIV induced hypoimmunity, or in close contact with any family members who has congenital immune diseases; Receive non-specific immunoglobulin within 1 month before recruitment; Subjects with acute febrile diseases with body temperature > 37.0 ℃ or infectious diseases; Subjects with a history of thrombocytopenia or other coagulation disorders that may be contraindicated for hypodermic injection; With known or suspected concurrent diseases include respiratory disease, acute infection or active chronic disease; With severe cardiovascular diseases (Pulmonary heart disease, Pulmonary edema, hypertension cannot be controlled to normal range by drugs), liver and kidney diseases and diabetic complications; Various infectious, suppurative or allergic dermatitis; Other circumstances judged by investigators that are not suitable for this clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shaobai Zhang
Organizational Affiliation
Shaanxi Provincial Center for Disease Control and Prevention
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yangxian Center for Disease Control and Prevention
City
Hanzhong
State/Province
Shaanxi
ZIP/Postal Code
723399
Country
China
Facility Name
Mianxian Center for Disease Control and Prevention
City
Hanzhong
State/Province
Shaanxi
ZIP/Postal Code
724200
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of the Safety and Immunogenicity of Hepatitis A Vaccine

We'll reach out to this number within 24 hrs